The future of critical care

The future of critical care is high-precision automation
Adaptive to each individual patient
Automatically implementing goals set by the clinician
Repeatably, economically, at scale

Introducing the Admetsys clinical robotics system
Learn more

Admetsys clinical robotics system

For blood analysis and metabolic control
In critical care and surgery


Clinical automation controller

  • Captures data from one or more biosensors
  • Constructs an evolving computational (AI) model of each patient's metabolism in real time
  • Autonomously regulates patient glucose with zero clinician intervention, directly infusing continuously-optimized insulin and dextrose therapy

Intravenous Laboratory™

Real-time continuous blood diagnostics

  • Provides automated extracorporeal whole-blood biosensing with zero blood loss to the patient
  • Cartridge-based design with 4 analytes: blood glucose, lactate, temperature, hematocrit (expandable to 20 analytes), providing up to 7 days of continuous biosensing
  • Enables early detection and mitigation of sepsis, informs PrecisionOne's glucose regulation function

Clinical dynamics

Metabolism in critical care

Controlling glucose in critical care settings is medically essential, sustaining the body's ability to defend against acute complications and effectively heal. This is a vital factor for 80% of critical care patients, regardless any prior diagnosis of diabetes. Similarly, early detection of sepsis, for which lactate is a key diagnostic indicator, is pivotal to survivability. The combined impact of these is substantial:

ICU stay
Glucose control 34% 1.8 days $9,900
Sepsis mitigation 30% 2.3 days $7,400
per patient

Metabolic parameters such as glucose and lactate can change rapidly in critical care patients. Seeing variability accurately in real time is crucial. This requires:

  • Sufficiently high frequency of measurement; and
  • Measurement in blood, since interstitial fluid is unreliable under pathophysiologies of critical care (edema, fluctuations in interstitial volume, temperature, and oxygen concentration).

This combination is precarious, since frequent blood draws often lead to hospital-acquired anemia, which requires transfusion.

Workflow and efficiency

To date, the standard of care for blood chemistry analysis and glucose control has been entirely manual. The clinical team draws blood, measures its chemistry using a lab analyzer or handheld instrument, calculates an insulin dose, and adjusts an infusion pump to administer the therapy. The clinical burden of this is significant and occurs in the context of shortages in skilled clinical personnel and escalating demand:

  • 7 min/hr occupying 2 nurses
  • 42% shortage in nurse staffing projected by 2030

This process limits the standard of care, the number of patients who may be cared for, or both.

Previously unachievable precision

Everything thus far has been a compromise out of necessity. High-precision automation changes this equation.

PrecisionOne™ clinical performance

Admetsys has conducted 3 clinical trials in the United States with outstanding outcomes:

  • 97% control between 80–125 mg/dL
  • 100% prevention of hypoglycemia under 70 mg/dL
  • 2.5 hrs mean time to normoglycemia
PrecisionOne™ Current care
Glucose control in target range
97% 66%
Prevention of hypoglycemia
100% 79%
Labor intensity
Clinician intervention (hourly)
0 14 min
80–125 mg/dL 70–180 mg/dL


Admetsys is headquartered in Boston, MA USA.

We would love to hear from you.